---
document_datetime: 2025-04-09 14:50:21
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.037945
conversion_datetime: 2025-12-28 18:32:40.469414
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ronapreve

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------|
| II/0017              | Extension of indication to include treatment of paediatric patients from 2 to less than 12 years old, weighing at least 10kg, who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 for Ronapreve, based on final results from study COV-2067; this was | 30/01/2025                          | 28/02/2025                                  | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion Ronapreve EMEA/H/C/005814/II/0017 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | a seamless, adaptive, Phase 3, randomised, double- blinded, placebo-controlled, multi-centre study to evaluate the efficacy, safety, and tolerability of casirivimab+imdevimab combination therapy in paediatric and adult outpatients with mild to moderate COVID-19. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. A revised RMP version 4.1 has also been approved. In addition, the MAH took the opportunity to bring the PI of both strengths in line with the current QRD template version 10.4, Annex of the excipient's guideline. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                                                                                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10963 /202407 | Periodic Safety Update EU Single assessment - casirivimab / imdevimab (Ronapreve)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/02/2025 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                              |
| II/0015             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/04/2024 | 05/07/2024 | SmPC and PL | Update of section 4.6 of the SmPC with information related to pregnancy based on the results from the drug pregnancy registry cohort (PDC study GV44373), as well as data from clinical studies and post-marketing surveillance. For more information, please refer to the Summary of Product Characteristics. |
| II/0014             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/02/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| PSUSA/10963 /202307   | Periodic Safety Update EU Single assessment - casirivimab / imdevimab (Ronapreve)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/02/2024   | n/a        |                        | PRAC Recommendation - maintenance                                   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------|
| IA/0016               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31/01/2024   | 05/07/2024 | Annex II               |                                                                     |
| PSUSA/10963 /202301   | Periodic Safety Update EU Single assessment - casirivimab / imdevimab (Ronapreve)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/08/2023   | n/a        |                        | PRAC Recommendation - maintenance                                   |
| IA/0012               | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 04/07/2023   | 05/07/2024 | SmPC                   |                                                                     |
| II/0002               | Extension of indication to include treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS- CoV-2 antibody test result for Ronapreve; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1 ,5.2 and 6.6 of the SmPC are updated. The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 26/04/2023   | 26/05/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Ronapreve-H-C- 005814-II-002 |
| II/0010/G             | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial                                                                                                                                                                                                                                                                                                                                                                                                                                   | 04/05/2023   | n/a        |                        |                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009             | Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning for convulsive syncope to the list of adverse drug reactions (ADRs) with frequency not known, following a signal assessment conducted by MAH. The Package Leaflet is updated accordingly C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                        | 26/01/2023 | 24/02/2023 | SmPC and PL | SmPC new text In the current variation the convulsive syncope is added to sections 4.4 and 4.8 of the SmPC. This has been observed following intravenous and subcutaneous administration. Convulsive syncope is a sign or symptom of infusion- related reactions, hypersensitivity reaction or considered to be part of a vasovagal reflex reaction associated with orthostatic hypotension... Convulsive syncope should be differentiated from seizures and managed as clinically indicated. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10963 /202207 | Periodic Safety Update EU Single assessment - casirivimab / imdevimab (Ronapreve)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/02/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| PSUSA/10963 /202201   | Periodic Safety Update EU Single assessment - casirivimab / imdevimab (Ronapreve)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 01/09/2022   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IB/0006/G             | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters | 12/07/2022   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent specification parameter corresponding test method B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS,   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |      |                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/07/2022 | n/a        |      |                                                                                                                                               |
| IA/0004/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 10/05/2022 | n/a        |      |                                                                                                                                               |
| II/0001   | Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update information on the in vitro neutralization activity of casirivimab/imdevimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                | 04/03/2022 | 07/03/2022 | SmPC | In vitro data suggest that the SARS-CoV-2 B.1.1.529 (Omicron) variant shows reduced susceptibility against casirivimab/imdevimab (Ronapreve). |